Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [Lu-177-DOTA(0),Tyr(3)]Octreotate

Esther Vliet, Casper van Eijck, Ronald de Krijger, EJN van Dijkum, JJ Teunissen, BL Kam, W.W. de Herder, R.A. Feelders, BA Bonsing, Tessa Brabander, Eric Krenning, Dik Kwekkeboom

Research output: Contribution to journalArticleAcademicpeer-review

94 Citations (Scopus)


Pancreatic neuroendocrine tumors (NETs) are rare neoplasms for which surgery has almost the only potential for cure. When surgery is not possible because of tumor size and vascular involvement, neoadjuvant treatment with [Lu-177-DOTA(0),Tyr(3)]octreotate (Lu-177-octreotate) may be an option. Methods: We studied 29 Dutch patients with a pathology-proven nonfunctioning pancreatic NET treated with Lu-177-octreotate. All patients had a borderline or unresectable pancreatic tumor (group 1) or oligometastatic disease (defined as liver metastases) (group 2). Progression-free survival (PFS) was analyzed using the Kaplan Meier method and Cox proportional hazards modeling. Results: After the treatment with Lu-177-octreotate, successful surgery was performed in 9 of 29 patients (31%). Six patients had a Whipple procedure, 2 patients had a pylorus-preserving pancreaticoduodenectomy, and 1 patient had a distal pancreatectomy and splenectomy. The median PFS was 69 mo for patients with successful surgery and 49 mo for the other patients. For comparison, the median PFS in 90 other patients with a nonfunctioning pancreatic NET with more than 3 liver metastases or other metastases was 25 mo. Conclusion: Neoadjuvant treatment with Lu-177-octreotate is a valuable option for patients with initially unresectable pancreatic NETs.
Original languageUndefined/Unknown
Pages (from-to)1647-1653
Number of pages7
JournalJournal of Nuclear Medicine
Issue number11
Publication statusPublished - 2015

Research programs

  • EMC MM-01-39-01
  • EMC MM-01-40-01
  • EMC MM-03-24-01
  • EMC MM-04-47-07

Cite this